Side-by-side · Research reference

Thymosin α-1vsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED8/39 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Thymosin α-1

Vilon

Primary target

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Immune cell differentiation pathways, chromatin modification

Pathway

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

—

Unknown — no HPA/HPG axis data

Origin

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

Thymosin α-1

Vilon

Standard dose (HBV/HCV)

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

—

Frequency

2× weekly (Mon/Thu typical)

Unknown — literature does not specify chronic administration protocols

Lower / starter dose

0.8 mg per injection

—

Evidence basis

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Mouse / in vitro only

Duration

6–12 months for chronic indications

Not characterised in humans

Reconstitution

Sterile water for injection per vial label

—

Timing

No specific time

—

Half-life

~2 hours plasma; tissue effect days

Not published — dipeptides typically <10 min plasma t½

Standard dose

—

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

04Side Effects & Safety

Parameter

Thymosin α-1

Vilon

Injection site reaction

Erythema, mild discomfort

—

GI symptoms

Rare nausea

—

Fatigue

Common during initial weeks

—

Fever / flu-like

Mild interferon-like response possible

—

Autoimmune

Theoretical risk; caution in active autoimmune disease

—

Cancer risk

No signal — used as adjuvant in oncology

—

Pregnancy / OB

Avoid

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Thymosin α-1

Vilon

1. Reconstitution

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

2× weekly, e.g. Monday + Thursday.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

27–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

Thymosin α-1

— no documented stacks

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020